A novel method for direct measurement of complement convertases activity in human serum
Version of Record online: 4 SEP 2014
© 2014 British Society for Immunology
Clinical & Experimental Immunology
Volume 178, Issue 1, pages 142–153, October 2014
How to Cite
Blom, A. M., Volokhina, E. B., Fransson, V., Strömberg, P., Berghard, L., Viktorelius, M., Mollnes, T. E., López-Trascasa, M., van den Heuvel, L. P., Goodship, T. H., Marchbank, K. J. and Okroj, M. (2014), A novel method for direct measurement of complement convertases activity in human serum. Clinical & Experimental Immunology, 178: 142–153. doi: 10.1111/cei.12388
- Issue online: 4 SEP 2014
- Version of Record online: 4 SEP 2014
- Accepted manuscript online: 22 MAY 2014 03:16AM EST
- Manuscript Accepted: 20 MAY 2014
- Swedish Research Council. Grant Numbers: K2012-66X-14928-09-5, K2010-80X-21514-01-4
- Ministerio de Economía y Competitividad. Spain. Grant Number: SAF2012-38636
- Dutch Kidney Foundation. Grant Numbers: IP10.22, KFB 11.007
- Foundations of Österlund
- Greta and Johan Kock
- Gustav V 80-years anniversary
- Tore Nilsson
- John and Augusta Persson
- Knut and Alice Wallenberg
- Inga-Britt and Arne Lundberg
Fig S1. Intra-assay coefficient of variation (intra-CV) of time of maximal convertase activity (Tmax) curves. Tmax curve for classical pathway (left panel) and alternative pathway (right panel) was calculated from four repetitions. Classical pathway convertase was formed from 0.5% normal human serum (NHS) blocked with 12.5 nM Ornithodoros moubata complement inhibitor (OmCI) or 2 nM eculizumab. Alternative pathway convertase was formed from 5% NHS blocked with 100 nM OmCI or 60 nM eculizumab.
Table S1. Detailed characteristics of clinical samples used in the study.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.